Cassava Sciences Inc vs Global X Lithium & Battery Tech ETF — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Global X Lithium & Battery Tech ETF trades at $74.79. The key difference: Global X Lithium & Battery Tech ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | LIT | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $4.64 | $91.62 |
52-Week Low | $0.87 | $44.96 |
Enterprise Value | -$34.93M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
LIT trades at $74.01, up 2.21% today, with bullish technical signals from moving averages but caution from oscillators. The stock has doubled over the past year, driven by strong momentum in electric vehicles, energy storage, and semiconductors. Recent news highlights global EV sales growth and China's ambitious 30% fleet target by 2030, supporting the lithium and battery technology theme.
Outlook remains positive given structural EV adoption trends, though overbought RSI levels suggest near-term consolidation risk. Key risks include Chinese export controls, regulatory changes, and competitive pressures. Analyst sentiment is constructive with buy ratings emphasizing long-term growth catalysts in clean energy transition.
Trailing returns across standard periods
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →